Two Partnerships Tackle Status Quo In Hemophilia, One With Long-Acting Coagulation Factors, Other With Increased Access To Therapy
Executive Summary
Although not among the more prominent diseases in the biopharmaceutical business, hemophilia offers significant market opportunity just the same, especially considering that people with the disease, a genetic blood disorder caused by scarcity or absence of coagulation factors, are underserved
You may also be interested in...
Finding Inspiration: Ipsen Builds Fourth Specialist Franchise With Hemophilia Deal
Deal in some ways mirrors Ipsen's July 2006 agreement with Tercica in endocrinology.
Biovitrum Creates Rare-Disease Focused Spec Pharma with Swedish Orphan Buy
The Swedish biotech pays roughly $500 million for a company with a revenue stream from commercial products as part of its transition into a spec pharma.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011